PapersPMID:36307493
Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 6 months
- Dose studied, every finding
- 550 mg x 4 tablets per time, twice a day, 24 weeks, oral
What moved
How to read these marks →“The changes in creatinine (Cre) at the 12th week (−0.1 ± 0.3) and 24th week (−0.2 ± 0.4) during oligo-fucoidan supplementation decreased more significantly than those in the control group at the 12th week (0.03 ± 0.07) and 24th week (0.07 ± 0.06) (p = 0.012 and p = 0.008).”
- Interests
- Industry funded
- Population
- Twenty adults with allergic asthma; both arms received regular asthma treatment; change from baseline at 12 and 24 weeks
“The change in WBC at 24th week (−1482.2 ± 1285.7) during supplementation with oligo-fucoidan decreased significantly more than that in the control group at 24th week (−589.0 ± 2835.0) (p = 0.038).”
- Interests
- Industry funded
- Population
- Twenty adults with allergic asthma; both arms received regular asthma treatment; change from baseline at 24 weeks
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Outpatients with allergic asthma (Kuang-Tien General Hospital) on regular asthma treatment, given oligo-fucoidan or placebo
- Participants
- 20
- Comparator
- placebo
- Duration
- 168 days
- Endpoints measured
- 97